Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, the maker of Ozempic, as the Danish drugmaker searches for a new chief executive amid a sharp decline in its share ...
BURLINGAME, Calif. & CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune ...
CALGARY, Alberta--(BUSINESS WIRE)--Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune ...
Genentech, a member of the Roche Group, today launched an up-to-$800 million partnership with Parvus Therapeutics to develop, manufacture, and commercialize new treatments for inflammatory bowel ...
Genentech has teamed up with Parvus Therapeutics to develop immune tolerance drugs. The Roche subsidiary put together an $800 million-plus deal to work with Parvus on drugs to treat autoimmune ...
Novartis, which has had a busy week for its CAR-T and NASH programs, today moved onto diabetes after penning a new pact with virtual Canadian biotech Parvus Therapeutics to use its leading tech. Exact ...
Parvus Corporation has announced a contract with the Naval Surface Warfare Center (NSWC) in Panama City, Florida to develop a ruggedized version of the Cisco 3825 Integrated Services Router (ISR) for ...
SALT LAKE CITY, UT--(Marketwire - Mar 18, 2013) - Eurotech subsidiary Parvus Corporation announces that the DuraCOR 830, a rugged tactical mission processor subsystem based on an ultra-low power Intel ...
Eurotech subsidiary Parvus Corporation announced today a contract with Rockwell Collins to supply 53 DuraCOR 810 mission computer subsystems in support of the Joint Precision Approach and Landing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results